Influenza virus neutralizing peptidomimetic compounds
The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.
1. A peptidomimetic compound having the sequence:
Cap1-X1-X2-X3-X4-X5-X6-X7-X8-Leu-X9-X10-Cap2
wherein:
Cap1 is an amino acid sequence comprising from 0-10 residues with a N-terminal blocking group;
X1 is any L or D-amino acid;
X2 is any L-amino acid;
X3 is an aliphatic L-amino acid with a molecular weight below 200 Da;
X4 is any L-amino acid;
X5 is Tyr or a L-tyrosine analog;
X6 is Phe or a L-phenylalanine analog;
X7 is any charged or neutral hydrophilic L-amino acid;
X8 is Trp or a L-tryptophan analog;
X9 is absent or any hydrophilic L-amino acid;
X10 is any L-amino acid; and
Cap2 is an amino acid sequence comprising from 0-10 residues with a C-terminal blocking group,
and wherein the compound is capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains comprising HA of two different subtypes from phylogenetic group 1.
2. The peptidomimetic compound according to claim 1 , wherein
X3 is an aliphatic L-amino acid with a molecular weight below 200 Da with a linear or C-gamma-branched side chain;
X5 is Tyr or a L-tyrosine analog having a hydrogen bond donor and/or acceptor replacing the hydroxyl group of tyrosine;
X6 is Phe or a L-phenylalanine analog with one or more substituents selected from the group consisting of hydrogen, halogen, a C1-C4 alkyl on the ortho and/or meta position of the phenyl ring, a halogen at the para position of the phenyl ring, L-3-naphthalene-1-yl-alanine; and L-3-naphthalene-2-yl-alanine; and
X8 is Trp or a L-tryptophan analog with a halogen substituent at C5, C6 and/or C7, and/or a small aliphatic substituent on C2 of the indole ring.
3. The peptidomimetic compound according to claim 1 , wherein the compound is cyclized.
4. The peptidomimetic compound according to claim 1 , wherein
X2 and/or X4 is any L-amino acid with a functional group that can be used for cyclization, wherein the functional group is 2-5 atoms away from the C-alpha atom of the L-amino acid; and
X10 is any L-amino acid with a functional group that can be used for cyclization, wherein the functional group is 2-5 atoms away from the C-alpha atom of the L-amino acid.
5. The peptidomimetic compound according to claim 3 , wherein the compound is cyclized via a chemical bridge between residues X2 and X10.
6. The peptidomimetic compound according to claim 3 , wherein the compound is cyclized via the formation of an amide bond comprising residues X2 and X10.
7. The peptidomimetic compound according to claim 6 , wherein X2 is Lys or L-ornithine, and X10 is beta-alanine, 3-aminoproprionic acid, 3-amino-2,2-dimethyl-proprionic acid, 4-aminobutanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, or Pro.
8. The peptidomimetic compound according to claim 6 , wherein X2 is Asp or Glu, and X10 is Lys or L-ornithine.
9. The peptidomimetic compound according to claim 3 , wherein the compound is cyclized via a chemical bridge between residues X4 and X10.
10. The peptidomimetic compound according to claim 3 , wherein the compound is cyclized via the formation of an amide bond comprising residues X4 and X10.
11. The peptidomimetic compound according to claim 10 , wherein X4 is Lys or L-ornithine, and X10 is beta-alanine, 3-aminoproprionic acid, 3-amino-2,2-dimethyl-proprionic acid, 4-aminobutanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, or Pro.
12. The peptidomimetic compound according to claim 10 , wherein X4 is Asp or Glu, and X10 is Lys or L-ornithine.
13. The peptidomimetic compound according to claim 3 , wherein the compound is cyclized via a chemical bridge between residues X2 and X10 and X4 and X10.
14. The peptidomimetic compound according to claim 13 , wherein the compound is cyclized by intramolecular cross-linking of free amine groups introduced at residues X2 and X4 and X10 with tris-succinimidyl aminotriacetate (TSAT).
15. A multimeric peptidomimetic compound comprising two or more compounds according to claim 1 .
16. The multimeric compound according to claim 15 , wherein the compound is dimeric.
17. The multimeric compound according to claim 15 , wherein the compound has been dimerized by intermolecular cross-linking of reactive groups introduced at residue X4.
18. The peptidomimetic compound according to claim 1 , wherein Cap1 is acetyl or succinyl.
19. The peptidomimetic compound according to claim 1 , wherein X1 is (S)-2-amino-5-phenylpentanoic acid, (2S)-3,3-dimethyl-2-amino-5-phenylpentanoic acid or Arg.
20. The peptidomimetic compound according to claim 1 , wherein X2 is Lys, L-ornithine, Cys, L-homo-cysteine, or Ser.
21. The peptidomimetic compound according to claim 1 , wherein X3 is Leu, L-norleucine, L-cyclopentylalanine, L-cyclobutylalanine, L-cyclopropylalanine, (2S,4S)-2-amino-4-methylhexanoic acid, (2S,4R)-2-amino-4-methylhexanoic acid, (2S,4S)-2-amino-4-methylheptanoic acid, (2S,4R)-2-amino-4-methylheptanoic acid, (S)-2-amino-4-ethylhexanoic acid, and all N-methylated derivatives thereof.
22. The peptidomimetic compound according to claim 1 , wherein X4 is Asp, Glu, Arg, Lys, ornithine, cysteine, homocysteine, N6-(4-carboxybutanoyl)lysine, or N5-(4-carboxybutanoyl)ornithine.
23. The peptidomimetic compound according to claim 1 , wherein X5 is Tyr.
24. The peptidomimetic compound according to claim 1 , wherein X6 is Phe, L-2-chlorophenylalanine, L-3-chlorophenylalanine, L-4-chlorophenylalanine, or L-3,4-dichlorophenylalanine.
25. The peptidomimetic compound according to claim 1 , wherein X7 is Glu, Gln, Asp, Asn, Arg or Lys.
26. The peptidomimetic compound according to claim 1 , wherein X8 is Trp or L-2-methyl-tryptophan.
27. The peptidomimetic compound according to claim 1 , wherein X9 is Ser or Gln.
28. The peptidomimetic compound according to claim 1 , wherein X10 is 4-aminobutanoic acid, beta-alanine, ((2R)-3-amino-2-(3-aminopropanoylamino) beta-alanine, Lys, L-ornithine, Cys or homocysteine.
29. A peptidomimetic compound having the sequence:
Cap1-X1-X2-X3-X4-X5-X6-X7-X8-Leu-X9-X10-Cap2
wherein:
Cap1 is an amino acid sequence comprising from 0-10 residues with a N-terminal blocking group;
X1 is any L or D-amino acid;
X2 is any L-amino acid;
X3 is an aliphatic L-amino acid with a molecular weight below 200 Da;
X4 is any L-amino acid;
X5 is Tyr or a L-tyrosine analog;
X6 is Phe or a L-phenylalanine analog;
X7 is any charged or neutral hydrophilic L-amino acid;
X8 is Trp or a L-tryptophan analog;
X9 is absent or any hydrophilic L-amino acid;
X10 is any L-amino acid; and
Cap2 is absent or carboxamide,
and wherein the compound is capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains comprising HA of two different subtypes from phylogenetic group 1.
30. A pharmaceutical composition comprising a peptidomimetic compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
31. A method of treating influenza in a subject in need thereof, the method comprising administering to the subject in need thereof a peptidomimetic compound according to claim 1 .
32. A method of preventing influenza in a subject, the method comprising administering to the subject a peptidomimetic compound according to claim 1 .